This report was first published by Endpoints News. To see the original version, click here
A softened version of the Biosecure Act has moved closer to final passage in Congress, but the bill could still shift US biopharma supply chains.
On Sunday, House and Senate leadership released the text of the National Defense Authorization Act, an annual bill that would, among other things, block certain Chinese biotech suppliers from federal contracts.
您已閱讀16%（445字），剩余84%（2291字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。